Poor Biological Factors and Prognosis of Interval Breast Cancers: Long-Term Results of Bahçeşehir (Istanbul) Breast Cancer Screening Project in Turkey

Neslihan Cabiloğlu, MD, PhD; Sibel Özkın Gürdal, MD; Arda Kayhan, MD; Nilüfer Özaydın, MD; Cennet Şahin, MD; Ömür Can, MD; Beyza Özcınar, MD; Gönül Akyüter, MD; Gülçin Vatandaş; Erkin Aribal, MD; and Vahit Özmen, MD

PURPOSE The Turkish Bahçeşehir Breast Cancer Screening Project was a 10-year, organized, population-based screening program carried out in Bahçeşehir county, Istanbul. Our aim was to examine the biologic features and outcome of screen-detected and interval breast cancers during the 10-year study period.

METHODS Between 2009 and 2019, 2-view mammograms were obtained at 2-year intervals for women aged 40 to 69 years. Clinicopathological characteristics including ER, PR, HER2-neu, and Ki-67 status were analyzed for those diagnosed with breast cancer.

RESULTS In 8,758 screened women, 131 breast cancers (1.5%) were detected. The majority of patients (82.3%) had prognostic stage 0-I disease. Contrarily, patients with interval cancers (n = 15; 11.4%) were more likely to have a worse prognostic stage (II-IV disease; odds ratio [OR], 3.59, 95% CI, 0.9 to 14.5) and high Ki-67 scores (OR, 3.14; 95% CI, 0.9 to 11.2). Interval cancers detected within 1 year were more likely to have a luminal B (57.1% vs 31.9%) and triple-negative (14.3% vs 1%) subtype and less likely to have a luminal A subtype (28.6% vs 61.5%; P = .04). Patients with interval cancers had a poor outcome in 10-year disease-specific (DSS) and disease-free survival (DFS) compared with those with screen-detected cancers (DSS: 68.2% vs 98.1%, P = .002; DFS: 78.6% vs 96.5%, P = .011).

CONCLUSION Our findings suggest the majority of screen-detected breast cancers exhibited a luminal A subtype profile with an excellent prognosis. However, interval cancers were more likely to have aggressive subtypes such as luminal B subtype or triple-negative cancers associated with a poor prognosis requiring other preventive strategies.

JCO Global Oncol 6:1103-1113. © 2020 by American Society of Clinical Oncology

INTRODUCTION

Meta-analyses of randomized studies have demonstrated that mammography screening decreased breast cancer mortality in women aged 39 to 59 years and age 60 to 69 years by approximately 15% and 32%, respectively. A recent meta-analysis of 60 studies in Europe also reported a mortality reduction ranging between 33% and 43% for Northern Europe, 43% and 45% for Southern Europe, and between 12% and 58% for Western Europe. In recent years, there has been much debate on the benefit of mammographic screening related with overdiagnosis and overtreatment. Screen detection was associated with increased disease-specific survival (DSS) compared with symptom-detected breast cancer, independent of early stage and favorable prognostic clinicopathological factors. This stage-adjusted reduction in breast cancer mortality has been partially attributed to higher detection rates on screening of slow-growing, indolent tumors with low metastatic potential that would never cause symptoms or death.

Screen-detected cancers are more often smaller tumors that are lymph node negative, estrogen receptor (ER)-positive, and of low grade, compared with interval cancers. Studies using the prognostic molecular subtypes defined by expression profiling (ie, luminal, HER2-positive, and basal) have shown that screen-detected tumors are more likely to be luminal A subtype and less likely to be basal-like, consistent with improved outcomes.

In Turkey, as a developing country bridging eastern Europe and the Middle East region, there are currently no nationwide, organized, population-based mammographic screening programs, and mostly opportunistic screening has been performed. The Turkish Bahçeşehir Breast Cancer Screening Project is a 10-year, organized, population-based screening program (between 2009 and 2019) carried out in women aged...
The prognosis and distinguishing pathologic features of interval cancers were investigated to outline their different characteristics in the first, organized, population-based screening program in Istanbul, Turkey.

Knowledge Generated
In 8,758 women screened after age 40 years biannually, the majority of the 131 cancers were detected at prognostic stage 0-1. Patients with interval cancers (11%) presented with a more advanced stage, poor prognosis, and higher Ki-67 scores.

Relevance
Interval cancers of more aggressive subtypes and with a poor prognosis may require other early detection and prevention strategies.

Context

Key Objective
The prognosis and distinguishing pathologic features of interval cancers were investigated to outline their different characteristics in the first, organized, population-based screening program in Istanbul, Turkey.

Knowledge Generated
In 8,758 women screened after age 40 years biannually, the majority of the 131 cancers were detected at prognostic stage 0-1. Patients with interval cancers (11%) presented with a more advanced stage, poor prognosis, and higher Ki-67 scores.

Relevance
Interval cancers of more aggressive subtypes and with a poor prognosis may require other early detection and prevention strategies.

Methods

Study Population
All patients with breast cancer detected during the Bağcıklı Breast Cancer Screening Project were included in the study. Screening was performed for 8,758 women registered to the Bağcıklı Breast Cancer Screening Center between January 2009 and January 2019 every 2 years in 5 to 10 sequential rounds. However, women with a family history of breast cancer underwent annual mammographic screening. Approval of the Institutional Review Board of Istanbul University was obtained. National Health Authorities were informed and approval was obtained. Each eligible woman signed a written informed consent.

Screening Procedure
Data from the first invitation to screening was defined as the starting point. Two views, (mediolateral oblique), and craniocaudal, of each breast were obtained. All examinations were double read by 2 independent radiologists who were blinded to each other’s interpretations. The discordant cases were also evaluated by a third experienced breast radiologist for the definitive final decision. Mammographic findings and breast density were classified according to Breast Imaging Reporting and Data System (BI-RADS) of the American College of Radiology.21

Women with a mammogram classified as BI-RADS 0 were recalled for additional imaging workup, including spot compression and magnification views, ultrasonography, or magnetic resonance imaging (MRI). In case of suspicious abnormality or one highly suggestive of malignancy (BI-RADS 4 or 5 cases) in the final report, the radiologists decided on whether to proceed to an additional workup such as core needle aspiration biopsy guided by ultrasonography (14-16 gauge), or a vacuum-assisted, large-core (9-10 gauge) stereotactic biopsy. The diagnostic process was completed within 4 weeks to minimize the period of uncertainty. Patients with a diagnosis of cancer were referred to university hospitals for treatment, including surgery, chemotherapy, hormone therapy, and radiotherapy. Patients underwent regular follow-up every 3 to 6 months for 5 years after completion of their therapies, and were seen yearly after 5 years after diagnosis.

According to the European Union Breast Cancer Screening Quality Guidelines, screen-detected cancers were defined as breast cancers that were mammographically detected in the first or a subsequent screening rounds. Interval cancer is defined as symptomatic cancer diagnosed within 24 months of a negative screening by mammography with or without additional assessment, including ultrasonography in selected cases. Furthermore, missed cancers were defined as the diagnosis of cancer after a false-negative mammogram.

Clinicopathological Characteristics
The following clinical and pathologic factors, along with intrinsic subtypes of breast cancer (ie, luminal A, luminal B, nonluminal HER2, and triple negative), were analyzed: age, tumor localization, the histopathological type, histologic grade, lymphovascular invasion, nodal status, multifocality, and ER, progesterone receptor (PR), and HER2-neu overexpression. ER or PR positivity was considered positive in any nuclear staining ≥ 1%. HER2-neu overexpression was considered either by immunohistochemistry 3+ or fluorescent in situ hybridization or silver-enhanced in situ hybridization positivity. The proliferative index Ki-67 was defined as the percentage of immunoreactive tumor cells of the total number of cells counted. The intrinsic subtypes of the tumor were defined as follows and as revised recently22-23: luminal A: ER+ or PR+, HER2-neu (−), Ki-67 < 20% (low proliferative activity); luminal B: ER+ or PR+, HER2-neu (+), Ki-67 ≥ 20% (high proliferative activity); nonluminal: HER2+, ER−, PR−, HER2-neu (+); triple negative: ER−, PR−, HER2-neu (−).
The AJCC Cancer Staging Manual, 8th edition, was used in the staging of patients considering the ER, PR, and HER2-neu expressions of tumors to determine the prognostic stage of patients’ disease, in addition to anatomic stage.

Statistical Analysis

To assess the associations between the documented variables and interval cancer status, each parameter was tested by using the Fisher exact test or χ² test in 2-tailed univariate analyses. To explore the clinicopathological characteristics of true interval cancers, the radiologically missed cancers (n = 9) were excluded from the study cohort in categorical statistical analysis. Independent variables included the various clinicopathologic variables. In addition, binary logistic regression analysis was used to assess the significant associations associated with interval cancer detection rate. The dependent variable was the interval cancer detection rate. Results were reported as odds ratio (OR) with 95% CIs.

Furthermore, Kaplan-Meier survival analyses were performed to examine the disease-free survival (DFS) and DSS rates to determine the factors associated with prognosis in patients with invasive breast cancer. Log-rank test was used to analyze the difference between 2 groups to compare the prognostic effect of different variables. Radiologically missed cancers were excluded from the study cohort in log-rank test analyses to explore the prognostic effect of true interval cancer compared with other prognostic factors, including clinicopathological factors. Cox regression analyses were used to assess the hazard ratio of factors associated with prognosis. A P ≤ 0.05 was considered statistically significant. The SPSS, version 17.0 (IBM, Armonk, NY) was used in statistical analyses.

RESULTS

A total of 131 breast cancers (1.5%) were detected. The median patient age was 52 (range, 40-73) years. Of the 131 patients with breast cancer, 52 (39.7%) were younger than 50 years, and the remaining 79 patients were older than 50 years. Of 131 cancers, 15 (11.5%) were true interval cancers that were detected after a negative screening by digital mammography within 24 (range, 0-23) months; 9 patients had radiologically missed cancers. Of 15 interval cancers, the majority (n = 9; 60%) were detected within 1 year (range, 0-11 months) after a negative biennial screening.

No significant difference was found between screen-detected and interval cancers with regard to demographic features, including age younger than 50 years, menopausal status, family history, use of hormone replacement therapy, and body mass index (Table 1). Screen-detected cancers were more likely to be found in the initial screening rounds, whereas interval cancers were more likely to be detected in the subsequent rounds, even though this difference did not reach statistical significance (47.7% vs 26.3%, respectively; P = .169; Table 1).

Of 128 patients who underwent surgery, the majority (n = 103; 80.5%) underwent breast conservation with or without sentinel lymph node biopsy (SLNB), whereas only 38 patients (29.7%) had axillary lymph node dissection (ALND) with or without SLNB the axillary procedure (Table 1). Furthermore, patients with interval cancers were more likely to undergo axillary dissection when compared with the screen-detected group (ALND in screen-detected group: 25.5% v ALND in interval cancer group: 53.8%; P = .049), which may be due to the increased initial clinical and/or pathologic presentation with axillary lymph node positivity (Table 2). Even though there was a trend for an increase in breast-conserving surgery rate in the screen-detected group, no significant difference was found in terms of breast operation type between the 2 groups.

Of 131 tumors, 114 (87%) were invasive cancers and 17 (13%) were ductal carcinoma in situ (DCIS). All DCIS tumors were detected in patients with screen-detected cancers (Table 2). Although there was an increased trend for a histopathology having an invasive ductal component, lymphovascular invasion, and multifocality and multicentricity in the interval cancers, compared with screen-detected cancers, there was no statistical significance between the groups (Table 2). The majority of patients with screen-detected cancers (87%) had prognostic stage 0-1, whereas 64.3% of patients with interval cancers had an early prognostic stage. Patients with screen-detected cancers were more likely to present with a tumor in an early anatomic stage and prognostic stage, whereas interval cancers presented in more advanced stages, as expected (Table 2).

Among invasive cancers, 91.4% were ER+ or PR+, whereas 15% were HER2-neu (+) and 64.5% had low Ki-67 positivity (< 20%). In terms of molecular subtypes, most of the invasive cancers were either luminal A (59.5%) or luminal B (31.5%), whereas other nonluminal HER2 (6.3%) and triple-negative cancers (2.7%) were detected less frequently (Table 3). Patients with interval cancers detected within 11 months of a negative screening were more likely to have high mammographic density, high Ki-67 positivity, and luminal B tumors, and less likely to have luminal A tumors, even though these associations did not reach statistical significance (Tables 1 and 3).

In logistic regression analysis, interval cancers were associated with more-advanced prognostic stages (prognostic stage II-IV v stage 0 and I; OR, 3.59; 95% CI, 0.9 to 14.5) and high Ki-67 positivity (Ki-67 ≥ 20% v < 20; OR, 3.14; 95% CI, 0.9 to 11.2) compared with patients with screen-detected cancers.

Outcome

Median follow-up was 58 (range, 12-124) months. Of all cases (n = 131), 10-year DFS and DSS rates were 94.6% and 96%, respectively. None of the patients with DCIS had a recurrence; the 5-year DSS and DFS rates were
both 100%. However, the 10-year DSS and DFS rates were 92.4% and 93.5%, respectively, for patients with invasive cancer. Patients with interval cancers (Fig 1) with an initial axillary positivity, tumor > 2 cm, multifocal and multicentric tumors, and with a more-advanced prognostic stage (ie, stage II-IV) were more likely to have a poorer DFS compared

### TABLE 1. Demographic and Clinical Factors Associated With Interval Breast Cancer in the Bahçeşehir Study

| Demographic or Clinical Factor | No. of Patients (N = 131) | Screen-Detected Cancer (n = 107) | Interval Cancer<sup>a,b</sup> (n = 15) | P<sup>c</sup> | Interval Cancer<sup>d</sup> (n = 9) | P<sup>e</sup> |
|------------------------------|----------------------------|----------------------------------|---------------------------------------|-----------|-----------------------------------|-----------|
| Age, years                   |                            |                                  |                                       |           |                                   |           |
| Median (range)               | 52 (40-73)                 | 52 (40-71)                       | 53 (46-73)                            | .994      | 53 (46-73)                        | .832      |
| 40-49                        | 52 (39.7)                  | 42 (39.3)                        | 5 (33.3)                              | .781      | 3 (33.3)                          | .999      |
| 50-69                        | 79 (60.3)                  | 65 (60.7)                        | 10 (66.7)                             |           | 6 (66.7)                          |           |
| Menopausal status<sup>f</sup> |                            |                                  |                                       | .999      |                                   | .999      |
| Premenopausal                | 67 (51.1)                  | 55 (51.4)                        | 8 (53.3)                              |           | 5 (55.6)                          |           |
| Postmenopausal               | 64 (48.9)                  | 52 (49.6)                        | 7 (46.7)                              |           | 4 (44.4)                          |           |
| Family history of breast cancer |                          |                                  |                                       | .746      |                                   | .216      |
| Positive                     | 30 (22.9)                  | 24 (22.4)                        | 4 (26.7)                              |           | 4 (44.4)                          |           |
| Negative                     | 101 (77.1)                 | 83 (77.6)                        | 11 (73.3)                             |           | 5 (55.6)                          |           |
| Hormone replacement therapy<sup>g</sup> (n = 64) |                            |                                  |                                       | .999      |                                   | .563      |
| Positive                     | 16 (19.1)                  | 13 (25)                          | 2 (28.6)                              |           | 0 (0)                             |           |
| Negative                     | 48 (80.9)                  | 39 (75)                          | 5 (71.4)                              |           | 4 (100)                           |           |
| BMI                          |                            |                                  |                                       | .773      |                                   | .493      |
| ≤ 25                         | 43 (32.8)                  | 35 (32.7)                        | 4 (26.7)                              |           | 4 (44.4)                          |           |
| > 25                         | 88 (67.2)                  | 72 (67.3)                        | 11 (73.3)                             |           | 5 (55.6)                          |           |
| Mammographic density, %      |                            |                                  |                                       | .255      |                                   | .118      |
| < 75                         | 123 (93.9)                 | 101 (94.4)                       | 13 (86.7)                             |           | 6 (75)                            |           |
| ≥ 75                         | 8 (6.1)                    | 6 (5.6)                          | 2 (13.3)                              |           | 2 (25)                            |           |
| Screening round              |                            |                                  |                                       | .169      |                                   | .177      |
| Initial                      | 59 (45)                    | 51 (47.7)                        | 4 (26.3)                              |           | 2 (22.2)                          |           |
| Subsequent                   | 72 (55)                    | 56 (52.3)                        | 11 (73.7)                             |           | 7 (77.8)                          |           |
| Surgery type (n = 128)<sup>h</sup> |                          |                                  |                                       | .242      |                                   | .334      |
| Breast surgery:              |                            |                                  |                                       |           |                                   |           |
| Breast-conserving surgery    | 103 (80.5)                 | 89 (84)                          | 9 (69.2)                              |           | 5 (71.4)                          |           |
| Mastectomy                   | 25 (19.5)                  | 17 (16)                          | 4 (30.8)                              |           | 2 (28.6)                          |           |
| Axillary surgery             |                            |                                  |                                       | .049      |                                   | .088      |
| ALND−                        | 90 (70.3)                  | 79 (74.5)                        | 6 (46.2)                              |           | 3 (42.9)                          |           |
| None (in cases with DCIS)    | 2 (1.6)                    | 2 (1.9)                          | 0 (0)                                 |           | 0 (0)                             |           |
| SLNB only                    | 88 (68.7)                  | 77 (72.6)                        | 6 (46.2)                              |           | 3 (42.9)                          |           |
| ALND+                        | 38 (29.7)                  | 27 (25.5)                        | 7 (53.8)                              |           | 4 (57.1)                          |           |
| SLNB and ALND               | 29 (22.7)                  | 20 (18.9)                        | 7 (53.8)                              |           | 4 (57.1)                          |           |
| ALND                         | 9 (7)                      | 7 (6.6)                          | 0 (0)                                 |           | 0 (0)                             |           |

**NOTE.** Data are reported as No. (%) unless otherwise indicated.

Abbreviations: ALND, axillary lymph node dissection; BMI, body mass index; DCIS, ductal carcinoma in situ; SLNB, sentinel lymph node biopsy.

<sup>a</sup>All cancers detected after a negative biennial screening within 2 years (range, 0-23 months).

<sup>b</sup>Radiologically missed cancers (n = 9) were excluded from the analysis.

<sup>c</sup>Comparative analyses between screen-detected and all interval cancers.

<sup>d</sup>All cancers detected after a negative biennial screening within 1 year (range, 0-11 months).

<sup>e</sup>Comparative analyses between screen-detected and interval cancers.

<sup>f</sup>Analyzed in postmenopausal patients.

<sup>g</sup>Data on 2 patients with advanced disease without surgery who only received chemotherapy, and missing data regarding a patient’s detailed pathology report that could not be received were excluded from the analysis.
### TABLE 2. Histopathological Characteristics Associated With Interval Cancers

| Tumor Characteristic                     | No. of Patients (%) (N = 131) | Screen Detected (n = 107) | Interval Cancer (n = 15) | $P^a$ | Interval Cancer (n = 9) | $P^b$ |
|------------------------------------------|-------------------------------|---------------------------|--------------------------|-------|------------------------|-------|
| Tumor size, cm                           |                               |                           |                          |       |                        |       |
| $\leq 2$ (T0 and T1)                     | 99 (75.6)                     | 84 (78.5)                 | 8 (53.3)                 | .052  | 3 (33.3)               | .007  |
| $>2$ (T2-4)                              | 32 (24.4)                     | 23 (21.5)                 | 7 (46.7)                 |       | 6 (66.7)               |       |
| Tumor type                               |                               |                           |                          | .216  |                        | .609  |
| DCIS                                     | 17 (13)                       | 17 (15.9)                 | 0 (0)                    | .457  | 0 (0)                  | .346  |
| Invasive cancer                          | 114 (87)                      | 90 (84.1)                 | 15 (100)                 | .457  | 9 (100)                | .346  |
| Tumor type                               |                               |                           |                          |       |                        |       |
| Invasive lobular                         | 19 (16.8)                     | 16 (18.2)                 | 1 (7.1)                  |       | 0 (0)                  |       |
| Other                                    | 94 (83.2)                     | 74 (81.8)                 | 13 (92.9)                |       | 8 (100)                |       |
| Tumor type                               |                               |                           |                          | .172  |                        | .329  |
| DCIS                                     | 17 (13.1)                     | 17 (15.9)                 | 0 (0)                    |       | 0 (0)                  |       |
| Invasive cancer subtypes                 |                               |                           |                          |       |                        |       |
| Invasive ductal carcinoma                | 78 (60)                       | 61 (57)                   | 10 (71.4)                |       | 6 (75)                 |       |
| Invasive lobular carcinoma               | 19 (14.6)                     | 16 (15)                   | 1 (7.1)                  |       | 0 (0)                  |       |
| Mix                                      | 5 (3.8)                       | 3 (2.8)                   | 2 (14.2)                 |       | 1 (12.5)               |       |
| Tubular                                  | 4 (3.1)                       | 4 (3.7)                   | 0 (0)                    |       | 0 (0)                  |       |
| Other                                    | 7 (5.4)                       | 6 (5.6)                   | 1 (7.1)                  |       | 1 (12.5)               |       |
| Modified histologic grade                |                               |                           |                          | .712  | .604                   |       |
| (invasive cancer)                        |                               |                           |                          |       |                        |       |
| 1 and 2                                  | 95 (88)                       | 72 (82.8)                 | 9 (75)                   |       | 4 (66.7)               |       |
| 3                                        | 28 (12)                       | 15 (17.2)                 | 3 (25)                   |       | 2 (33.3)               |       |
| Lymphovascular invasion (invasive cancer)|                               |                           |                          | .271  | 6.98                   |       |
| Negative                                 | 86 (76.3)                     | 68 (79.1)                 | 8 (66.7)                 |       | 4 (66.7)               |       |
| Positive                                 | 27 (23.7)                     | 18 (20.9)                 | 4 (33.7)                 |       | 2 (33.3)               |       |
| Tumor foci                               |                               |                           |                          | .155  | .629                   |       |
| Unifocal                                 | 99 (77.3)                     | 85 (80.2)                 | 8 (61.5)                 |       | 5 (71.4)               |       |
| Multifocal and multicentric              | 29 (22.7)                     | 21 (19.8)                 | 5 (38.5)                 |       | 2 (28.6)               |       |
| Initial presentation with axillary positivity |                           |                           |                          | .131  | .106                   |       |
| Yes                                      | 43 (33.1)                     | 31 (31)                   | 7 (50)                   |       | 5 (62.5)               |       |
| No                                       | 87 (66.9)                     | 76 (69)                   | 7 (50)                   |       | 3 (37.5)               |       |
| Anatomic stage                           |                               |                           |                          | .141  | .074                   |       |
| 0                                        | 17 (13.1)                     | 17 (15.9)                 | 0 (0)                    |       | 0                      |       |
| I                                        | 65 (50)                       | 55 (51.4)                 | 6 (42.9)                 |       | 4 (50)                 |       |
| II                                       | 30 (23.1)                     | 23 (21.5)                 | 4 (28.6)                 |       | 1 (12.5)               |       |
| III                                      | 16 (12.3)                     | 10 (9.3)                  | 4 (28.6)                 |       | 3 (37.5)               |       |
| IV                                       | 2 (1.5)                       | 2 (1.9)                   | 0 (0)                    |       | 0                      |       |
| Early anatomic stage (stage 0-I v II-IV) |                               |                           |                          | .083  | .024                   |       |
| Yes                                      | 82 (63.1)                     | 72 (67.3)                 | 6 (42.9)                 |       | 2 (25)                 |       |
| No                                       | 48 (36.9)                     | 35 (32.7)                 | 8 (57.1)                 |       | 6 (75)                 |       |
| Prognostic stage                         |                               |                           |                          | .053  | .027                   |       |
| 0                                        | 17 (13.1)                     | 17 (15.9)                 | 0 (0)                    |       | 0                      |       |
| I                                        | 90 (69.2)                     | 76 (71)                   | 9 (64.3)                 |       | 4 (50)                 |       |
| II                                       | 8 (6.2)                       | 5 (4.7)                   | 1 (7.1)                  |       | 1 (12.5)               |       |
| III                                      | 13 (10)                       | 7 (6.5)                   | 4 (28.6)                 |       | 3 (37.5)               |       |
| IV                                       | 2 (1.5)                       | 2 (1.9)                   | 0 (0)                    |       | 0                      |       |

(Continued on following page)
with other patients (Table 4). Similarly, patients with interval cancers (Fig 2) with initial axillary positivity and luminal A tumors were more likely to have a worse DSS compared with other patients (Table 4). Among patients with prognostic stage I, those with interval cancers were more likely to have a worse 10-year DFS and DSS compared with other patients with screen-detected cancers.

DISCUSSION

In recent years, the effectiveness of breast cancer screening has been strongly debated with regard to overdiagnosis and overtreatment.3 Many studies have found that screen-detected cancers have more favorable clinicopathologic factors and prognosis that might be associated with a different tumor biology compared with interval cancers.8-16,25-36 Patients with a screen-detected cancer were more likely to have a low- or even an ultralow-risk tumor compared with interval cancers assessed by the 70-gene signature.25,26 Specific copy number imbalances were also noted in screen-detected breast cancers associated with more favorable, indolent tumor genotypes and might contribute to the survival advantage associated with screening.27 Therefore, we investigated the molecular subtypes and clinicopathological characteristics and

### Table 2. Histopathological Characteristics Associated With Interval Cancers (Continued)

| Tumor Characteristic | No. of Patients (%) | Screen Detected (n = 107) | Interval Cancera,n = 15 Pd Interval Cancerb,n = 9 Pf |
|----------------------|---------------------|---------------------------|------------------------------------------------------|
| Early prognostic stage (stage I v II-IV) | | | |
| Yes | 107 (82.3) | 93 (86.9) | 9 (64.3) | .044 | .020 |
| No | 23 (17.7) | 14 (13.1) | 5 (35.7) | 4 (50) |

NOTE. Data are reported as No. (%) unless otherwise indicated.

Abbreviation: DCIS, ductal carcinoma in situ.

*Missing data regarding a patient’s detailed pathology report that could not be received were excluded from the analysis.

aAll cancers detected after a negative biennial screening within 2 years (range, 0-23 months).

bRadiologically missed cancers (n = 9) were excluded from the analysis in categorical analyses.

cComparative analyses between screen-detected and all interval cancers.

dAll cancers detected after a negative biennial screening within 1 year (range, 0-11 months).

eComparative analyses between screen-detected and interval cancers.

fAxillary positivity: pathologic nodal status for operable breast cancer and clinical for locally advanced breast cancer.

### Table 3. Molecular Subtype Analysis of Screen-Detected and Interval Invasive Breast Cancers

| Tumor Characteristic | Total | Screen-Detected Cancer | Interval Cancera,n = 15 Pd Interval Cancerb,n = 9 Pf |
|----------------------|-------|------------------------|------------------------------------------------------|
| Invasive cancer | | | |
| ER+ | 103 (91.2) (n = 113) | 84 (93.3) (n = 90) | 12 (85.7) (n = 14) .293 | 7 (87.5) (n = 8) .460 |
| PR+ | 93 (82.3) (n = 113) | 75 (83.3) (n = 90) | 11 (78.6) (n = 14) .706 | 6 (75) (n = 8) .624 |
| HER2/neu (+) | 17 (15) (n = 113) | 14 (15.6) (n = 90) | 2 (14.3) (n = 14) .999 | 1 (12.5) (n = 8) .999 |
| Ki-67 (≥ 20%) | 38 (35.5) (n = 107) | 29 (33) (n = 88) | 7 (58.3) (n = 12) .112 | 5 (71.4) (n = 7) .093 |
| Molecular subtype | | | |
| Luminal A | (n = 111) | (n = 96) | (n = 12) .259 | (n = 7) .039 |
| Luminal B | 66 (59.5) | 59 (61.5) | 5 (41.7) | 2 (28.6) |
| Nonluminal HER2/neu | 35 (31.5) | 30 (31.25) | 5 (41.7) | 4 (57.1) |
| Triple negative | 7 (6.3) | 6 (6.25) | 1 (8.3) | 0 (0) |
| Luminal type (ER+ or PR+) | 106 (91.4) (n = 116) | 87 (93.5) (n = 93) | 12 (85.7) (n = 14) .281 | 7 (87.5) (n = 8) .449 |
| Luminal A type | 66 (59.5) (n = 111) | 56 (61.5) (n = 91) | 5 (41.7) (n = 12) .221 | 2 (28.6) (n = 7) .118 |
| Luminal B type | 35 (31.5) (n = 111) | 29 (31.9) (n = 91) | 5 (41.7) (n = 12) .525 | 4 (57.1) (n = 7) .221 |

NOTE. Data are reported as No. (%) unless otherwise indicated.

Abbreviations: ER, estrogen receptor; PR, progesterone receptor.

*Missing data regarding a patient’s detailed pathology report that could not be received were excluded from the analysis.

aAll cancers detected after a negative biennial screening within 2 years (range, 0-23 months).

bRadiologically missed cancers (n = 9) were excluded from the analysis.

cComparative analyses between screen-detected and all interval cancers.

dAll cancers detected after a negative biennial screening within 1 year (range, 0-11 months).

eComparative analyses between screen-detected and interval cancers.
Breast cancer subtypes were identified by microarrays and immunohistochemistry and identified as luminal A, luminal B, nonluminal HER2-neu, and triple-negative tumors. Of those, luminal A tumors were associated with the most favorable clinical outcome. Previous studies demonstrated that the distribution of the molecular subtypes differed in screen-detected breast cancer compared with symptomatic cancers found outside of mammographic screening. Sihto et al reported that in the age group 50 to 69 years old, luminal type A was more common (73.3%) among screen-detected cancers compared with 63.8% of cancers found outside mammography screening, whereas the HER2+/ER− type was rare (5.7%) among screen-detected cancers. Crispo et al also reported increased detection rate of luminal A type cancers among screen-detected breast cancers compared with symptomatic ones. A significantly higher proportion of cases expressed PgR and had a Ki67 ≤ 20% among screen-detected cancers compared with symptomatic tumors (78.1% v 68%, P = .04; and 57.1% v 44.1%, P = .02, respectively). The majority of patients (64.5%) in our study had low Ki-67 scores (< 20%), consistent with the findings from the Sihto et al study, along with other reports. In an analysis of > 13,000 patients with breast cancer in the Turkish Federation of Breast Diseases Society Breast Cancer Registry, the luminal A molecular subtype was 62%, the luminal B was 15%, HER-2 neu was 8.5%, and triple-negative breast cancers were 15% in those patients with disease detected outside screening programs. In concordance with these studies, our results also show that the majority of the cancers detected in screening are luminal (91.4%) or even luminal A molecular subtype (59.5%), which is biologically the most favorable low-risk breast cancer, whereas the nonluminal HER2-neu subtype and triple-negative breast cancers were relatively rarely detected in our screening program. Furthermore, there was a trend toward an increased rate of triple-negative and luminal B type cancers and decreased rate of luminal A type tumors among interval cancers, compared with screen-detected group, consistent with reports from previous studies.

Mammographic screening detects breast cancer at an early stage associated with improved survival rates. In the recent analysis of the Turkish Federation of Breast Diseases Society Breast Cancer Registry, the rates of DCIS and stage I breast cancer at diagnosis were 4.7% and 27.5%, respectively. However, in our study, we detected at least a 2.5-fold increased rate in DCIS (13.1%) and almost a 2-fold increased rate of stage I breast cancer (50%) during our mammographic screening program. In 2017, the eighth revised edition of the TNM system was introduced, incorporating the prognostic-stage tables in addition to the traditional anatomic-stage tables by considering biomarker expressions such as ER, PR, and HER2-neu expression. In a recently published validation study, authors reported the prognostic stage provides more accurate prognostic information than does the anatomic stage alone, thus supporting the use of prognostic stage in breast cancer staging. In the current study, cancer in the majority of patients (82.3%) was detected at an early prognostic stage (0-I), and patients with interval cancers were more likely to have a worse prognostic stage (OR, 3.59; 95% CI, 0.9 to 14.5) with high Ki-67 scores (OR, 3.14; 95% CI, 0.9 to 11.2) compared with screen-detected cancers. Of note, patients with larger tumors, axillary positivity, multifocal/multicentric disease, advanced prognostic stage, nonluminal A tumors, and interval cancers were more likely to exhibit worse 5-year DSS and DFS, similar to what has been reported in some studies.

The poor prognosis associated with interval cancers has been suggested to be attributed to stage migration, depending on the higher incidence of larger size and axillary positivity. In this study, interestingly, we demonstrated a survival advantage in screen-detected cancers compared with interval cancers among patients with prognostic stage I. However, these findings seem to be contrary to those of O'Brien et al, who did not demonstrate any survival difference between interval cancers (n = 927) and screen-detected cancers (n = 3,078) after adjusting for some variables, including stage, grade, and tumor subtype. Similar to other studies, we also found that interval cancers more likely presented with larger tumor and with axillary positivity than did screen-detected cancers. In our screening program, the majority of patients with screen-detected tumors chose breast conservation (84%) and SLNB alone (73%). Similarly, in the Sihto et al study, the surgical approach tended to be more conservative.
TABLE 4. Demographic and Histopathological Factors Associated With Prognosis in Invasive Breast Cancer Detected in the Turkish Bahçeşehir Screening Program

| Prognostic Factor (n = 105) | 10-Year DSS (%) | P     | 10-Year DFS (%) | P     |
|----------------------------|-----------------|-------|-----------------|-------|
| Age, years                 |                 |       |                 |       |
| < 50                       | 89.6            | .281  | 90.9            | .480  |
| > 50                       | 98.3            |       | 96.2            |       |
| Tumor size, cm             |                 |       |                 |       |
| ≤ 2                        | 97.1            | .062  | 98.1            | .014  |
| > 2                        | 88.5            |       | 82.7            |       |
| Modified histologic grade  |                 |       |                 |       |
| 1 and 2                    | 97.1            | .188  | 98.2            | .191  |
| 3                          | 90              |       | 90              |       |
| Lymphovascular invasion    |                 |       |                 |       |
| Negative                   | 97.1            | .307  | 98              | .418  |
| Positive                   | 92.9            |       | 92.9            |       |
| Tumor foci                 |                 |       |                 |       |
| Unifocal                   | 96.7            | .102  | 98              | .022  |
| Multifocal and multicentric| 88.9            |       | 84              |       |
| Ki-67 (> 20%)              |                 |       |                 |       |
| Yes                        | 90.2            | .06   | 92.5            | .241  |
| No                         | 100             |       | 97.7            |       |
| Initial presentation with axillary positivity (pathologic and clinical for LABC) | | | | |
| Yes                        | 85.6            | .02   | 84.6            | .007  |
| No                         | 100             |       | 100             |       |
| Prognostic early stage (stage I v II-IV) | | | | |
| Yes                        | 95.9            | .367  | 97              | .05   |
| No                         | 88.9            |       | 80              |       |
| Interval cancer            |                 |       |                 |       |
| Yes                        | 68.2            | .002  | 78.6            | .011  |
| No                         | 98.1            |       | 96.5            |       |
| For prognostic stage I (n = 86); interval cancer | | | | |
| Yes (n = 10)               | 58.3            | .0001 | 74.1            | .0001 |
| No (n = 76)                | 100             |       | 100             |       |
| Luminal A type breast cancer|                 |       |                 |       |
| Yes                        | 100             | .036  | 97.7            | .131  |
| No                         | 87.5            |       | 89.2            |       |

Abbreviations: DFS, disease-free survival; DSS, disease-specific survival; LABC, locally advanced breast cancer.

*Patients with invasive cancer were considered in survival analyses. Radiologically missed cancers (n = 9) were excluded from the analysis.

in the screen-detected group compared with women who were symptomatic at diagnosis (88.0 vs 74.7%; P = .005). Furthermore, interval cancers detected within 1 year after a negative screening in our study were more likely to be associated with dense breasts, in concordance with Sala et al,40 who also found an association of interval cancers with more-advanced stage, denser breasts, and higher percentages of triple-breast cancers. We previously demonstrated that our population-based, organized screening project was feasible for women between ages 40 and 49 years in Turkey, with an attendance rate of 88.3% in the first round.20 The overall cancer detection rate was 4.8% per 10,000 women, and DCIS, stage I cancer, and axillary-node positivity rates were 22%, 61%, and 17%, respectively. Upon our findings that more than half of the patients had their cancer detected when they were younger than the age of 50 years in the first round in
2011, the Turkish Ministry of Health revised the national breast cancer-screening standards in 2012, recommending breast cancer screening be initiated at age 40 years instead of age 50 years and biennially up to age 69 years. Under this strategy, cancer in most of our patients was diagnosed at an early anatomic (63.1%) and prognostic (82.3%) stage in the current study. In addition, our screening program also was cost-effective in Turkey, which may be attributed to the early treatment modalities.41 Studies are needed to investigate whether our results might be relevant and adaptable to other Asian countries to establish policy recommendations on breast cancer early-detection strategies.42,43

![Figure 2](image_url)

**FIG 2.** Among patients with invasive cancer, those with interval cancers had a shorter disease-specific survival compared with those with screen-detected cancers (interval cancer, 68.2% vs screen-detected cancer, 98.1%; P = .002). Radiologically missed cancers (n = 9) and missing data (n = 4) were excluded from the analysis.

In conclusion, our findings suggest that the majority of screen-detected breast cancers mostly exhibit luminal A subtype, in concordance with previous studies from developed countries. However, more aggressive subtypes such as triple-negative cancers are less likely to be detected by mammographic screening programs and may require other imaging modalities, including abbreviated breast MRI.44 We are conducting an ongoing trial of abbreviated breast MRI to screen women with dense breasts. New strategies are required for improved screening in developing countries.

**AFFILIATIONS**
1Department of Surgery, Istanbul University, Istanbul Medical Faculty, Istanbul, Turkey
2Department of Surgery, Namik Kemal University, Faculty of Medicine, Tekirdag, Turkey
3Department of Radiology, Erzincan Binali Yıldırım University Faculty of Medicine, Erzincan, Turkey
4Department of Public Health, Marmara University, Faculty of Medicine, Istanbul, Turkey
5Department of Radiology, Şişli Etfal Research and Teaching Hospital, Istanbul, Turkey
6MEMEDER Screening Center, Bahçeşehir, Istanbul, Turkey
7Department of Radiology, Acıbadem University, Faculty of Medicine, Istanbul, Turkey

**CORRESPONDING AUTHOR**
Neslihan Cabioglu, MD, PhD, Department of Surgery, Istanbul University, Istanbul Faculty of Medicine, Zeytinlik mah. Odabasi sok. No: 47/10, Bakirkoy, Istanbul, 3471, Turkey; e-mail: neslicab@yahoo.com

**SUPPORT**
Supported by a grant from Roche (V.O.) and Başakşehir (Bahçeşehir is a region in the Başakşehir county in Istanbul) Municipality.

**AUTHOR CONTRIBUTIONS**
Conception and design: Neslihan Cabioglu, Nilüfer Özaydın, Cennet Şahin, Beyza Özçinar, Erkin Aribal, Vahit Özmen
Administrative support: Vahit Özmen
Provision of study material or patients: Sibel Özkan Gürdal, Beyza Özçinar, Vahit Özmen

**DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST**
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/go/site/misc/authors.html.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

**Beyza Özçinar**
Research Funding: Roche

No other potential conflicts of interest were reported.

**ACKNOWLEDGMENT**
We thank the Bahçeşehir Breast Screening Facilities; Ayten Balikçıkoglu, MD; Nursen Has; Sevil Sevinç; Deniz Doğan Özkanlı; Ahu Özdemir; and Semra Yaşar, in particular, for providing the screening data used in this study. We are grateful to all Turkish women who participated in this trial.

**Long-Term Results of Turkish Breast Screening Project**

---

**FIG 2.** Among patients with invasive cancer, those with interval cancers had a shorter disease-specific survival compared with those with screen-detected cancers (interval cancer, 68.2% vs screen-detected cancer, 98.1%; P = .002). Radiologically missed cancers (n = 9) and missing data (n = 4) were excluded from the analysis.

In conclusion, our findings suggest that the majority of screen-detected breast cancers mostly exhibit luminal A subtype, in concordance with previous studies from developed countries. However, more aggressive subtypes such as triple-negative cancers are less likely to be detected by mammographic screening programs and may require other imaging modalities, including abbreviated breast MRI. We are conducting an ongoing trial of abbreviated breast MRI to screen women with dense breasts. New strategies are required for improved screening in developing countries.

**AFFILIATIONS**
1Department of Surgery, Istanbul University, Istanbul Medical Faculty, Istanbul, Turkey
2Department of Surgery, Namik Kemal University, Faculty of Medicine, Tekirdag, Turkey
3Department of Radiology, Erzincan Binali Yıldırım University Faculty of Medicine, Erzincan, Turkey
4Department of Public Health, Marmara University, Faculty of Medicine, Istanbul, Turkey
5Department of Radiology, Şişli Etfal Research and Teaching Hospital, Istanbul, Turkey
6MEMEDER Screening Center, Bahçeşehir, Istanbul, Turkey
7Department of Radiology, Acıbadem University, Faculty of Medicine, Istanbul, Turkey

**CORRESPONDING AUTHOR**
Neslihan Cabioglu, MD, PhD, Department of Surgery, Istanbul University, Istanbul Faculty of Medicine, Zeytinlik mah. Odabasi sok. No: 47/10, Bakirkoy, Istanbul, 3471, Turkey; e-mail: neslicab@yahoo.com

**SUPPORT**
Supported by a grant from Roche (V.O.) and Başakşehir (Bahçeşehir is a region in the Başakşehir county in Istanbul) Municipality.

**AUTHOR CONTRIBUTIONS**
Conception and design: Neslihan Cabioglu, Nilüfer Özaydın, Cennet Şahin, Beyza Özçinar, Erkin Aribal, Vahit Özmen
Administrative support: Vahit Özmen
Provision of study material or patients: Sibel Özkan Gürdal, Beyza Özçinar, Vahit Özmen

**DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST**
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/go/site/misc/authors.html.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

**Beyza Özçinar**
Research Funding: Roche

No other potential conflicts of interest were reported.

**ACKNOWLEDGMENT**
We thank the Bahçeşehir Breast Screening Facilities; Ayten Balikçıkoglu, MD; Nursen Has; Sevil Sevinç; Deniz Doğan Özkanlı; Ahu Özdemir; and Semra Yaşar, in particular, for providing the screening data used in this study. We are grateful to all Turkish women who participated in this trial.
REFERENCES

1. Nelson HD, Tyne K, Naik A, et al: Screening for breast cancer: An update for the U.S. Preventive Services Task Force. Ann Intern Med 151:727-737, W237-242, 2009
2. Zielonke N, Gini A, Jansen EEL, et al: Evidence for reducing cancer-specific mortality due to screening for breast cancer in Europe: A systematic review. Eur J Cancer 127:191-206, 2020
3. Independent UK Panel on Breast Cancer Screening: The benefits and harms of breast cancer screening: An independent review. Lancet 380:1778-1786, 2012
4. Zahl PH, Strand BH, Maehlen J: Incidence of breast cancer in Norway and Sweden during introduction of nationwide screening. Prospective cohort study. BMJ 328:921-924, 2004
5. Jørstengen KJ, Gatzsche PC: Overdiagnosis in publicly organised mammography screening programmes: Systematic review of incidence trends. BMJ 339:b2587, 2009
6. Kalager M, Adami HO, Brothauer M, et al: Overdiagnosis of invasive breast cancer due to mammography screening: Results from the Norwegian screening program. Ann Intern Med 156:491-499, 2012
7. Immomen-Rah P, Kauhava L, Panvinen I, et al: Mammographic screening reduces risk of breast carcinoma recurrence. Cancer 103:474-482, 2005
8. Shen Y, Yang Y, Inoue LY, et al: Role of detection method in predicting breast cancer survival: Analysis of randomized screening trials. J Natl Cancer Inst 97:1195-1203, 2005
9. Dong W, Berry DA, Bevers TB, et al: Prognostic role of detection method and its relationship with tumor biomarkers in breast cancer: The University of Texas M.D. Anderson Cancer Center experience. Cancer Epidemiol Biomarkers Prev 17:1096-1103, 2008
10. Joensuu H, Lehtimäki T, Holli K, et al: Risk for distant recurrence of breast cancer detected by mammography screening or other methods. JAMA 292:1064-1073, 2004
11. Chu KC, Smart CR, Tarone RE: Analysis of breast cancer mortality and stage distribution by age for the Health Insurance Plan clinical trial. J Natl Cancer Inst 80:1125-1132, 1988
12. Sihate H, Lundin J, Lehtimäki T, et al: Molecular subtypes of breast cancers detected in mammography screening and outside of screening. Clin Cancer Res 14:4103-4110, 2008
13. Nagtegaal ID, Allgood PC, Duffy SW, et al: Prognosis and pathology of screen-detected carcinomas: How different are they? Cancer 117:1360-1368, 2011
14. Dawson SJ, Duffy SW, Blows FM, et al: Molecular characteristics of screen-detected vs symptomatic breast cancers and their impact on survival. Br J Cancer 101:1338-1344, 2009
15. Chiarrelli AM, Edwards SA, Sheppard AJ, et al: Favourable prognostic factors of subsequent screen-detected breast cancers among women aged 50-69. Eur J Cancer Prev 21:499-506, 2012
16. Mook S, Van ’t Veer LJ, Rutgers EJ, et al: Independent prognostic value of screen detection in invasive breast cancer. J Natl Cancer Inst 103:585-597, 2011
17. Fidanes E, Eyser SY, Parkin DM: Incidence in Izmir in 1993-1994: First results from Izmir Cancer Registry. Eur J Cancer 37:83-92, 2001
18. Özmen V: Breast cancer in Turkey: Clinical and histopathological characteristics (analysis of 13,240 patients). J Breast Health 10:98-105, 2014
19. Kayhan A, Arbal E, Sahin C, et al: Radiologic findings of screen-detected cancers in an organized population-based screening mammography program in Turkey. Diagn Interv Radiol 22:508-513, 2016
20. Kayhan A, Gurald SO, Ozaydin N, et al: Successful first round results of a Turkish breast cancer screening program with mammography in Bahcesehir, Istanbul. Asian Pac J Cancer Prev 15:1693-1697, 2014
21. American College of Radiology: ACR BI-RADS®-Mammography: Breast Imaging Reporting and Data System, Breast Imaging Atlas. Vol 4. Reston, VA, American College of Radiology, 2003.
22. Sarrie T, Perou CM, Tibshirani R, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869-10874, 2001
23. Untch M, Gerber B, Harbeck N, et al: 13th St. Gallen International Breast Cancer Conference 2013: Primary therapy of early breast cancer evidence, controversies, consensus - opinion of a German team of experts (Zurich 2013). Breast Care (Basel) 8:221-229, 2013
24. Amin MB, Edge S, Greene F, et al (eds): AJCC Cancer Staging Manual. 8th ed. Springer, Basel, Switzerland, Springer, 2017:588
25. Drukker CA, Schmidt MK, Rutgers EJT, et al. Mammographic screening detects low-risk tumor biology breast cancers. Breast Cancer Res Treat 144:103-111, 2015
26. Esserman LJ, Shieh Y, Rutgers EJ, et al: Independent prognostic value of screen detection in invasive breast cancer. J Natl Cancer Inst 103:585-597, 2011
27. Iancu M, Calabrese N, Chen C, et al: The impact of mammographic screening on the detection of good and poor prognosis breast cancers. Breast Cancer Res Treat 130:725-734, 2011
28. Brewster AM, Thompson P, Sahin AA, et al: Copy number imbalances between screen- and symptom-detected breast cancers and impact on disease-free survival. Cancer Prev Res (Phila) 4:1609-1616, 2011
29. Crisp A, Barba M, D’Aluoto G, et al: Molecular profiles of screen detected vs. symptomatic breast cancer and their impact on survival: Results from a clinical series. BMC Cancer 13:15, 2013
30. Gilliland FD, Joste N, Stauberm PM, et al: Biologic characteristics of interval and screen-detected breast cancers. J Natl Cancer Inst 92:743-749, 2000
31. Groenendijk RP, Buit P, Tewarie L, et al: Screen-detected breast cancers have a lower mitotic activity index. Br J Cancer 82:381-384, 2000
32. Caldarera A, Pultit D, Crocetti E, et al: Biological characteristics of interval cancers: A role for biomarkers in the breast cancer screening. J Cancer Res Clin Oncol 139:181-185, 2013
33. Holloway CMB, Jiang L, Whitehead M, et al: Organized screening detects breast cancer at earlier stage regardless of molecular phenotype. J Cancer Res Clin Oncol 144:1769-1775, 2018
34. Lowery JT, Byers T, Kettelson J, et al: Differential expression of prognostic biomarkers between interval and screen-detected breast cancers: Does age or family history matter? Breast Cancer Res Treat 129:211-219, 2011
35. Domingo L, Sala M, Serruota S, et al: Phenotypic characterization and risk factors for interval breast cancers in a population-based breast cancer screening program in Barcelona, Spain. Cancer Causes Control 21:1165-1164, 2010
36. Lehtimäki T, Lundin M, Linder N, et al: Long-term recording of breast cancer detected by mammography screening or other methods. Breast Cancer Res Treat 13:R134, 2011
37. José Bento M, Gonzalves G, Aguiar A, et al: Clinicopathological differences between interval and screen-detected breast cancers diagnosed within a screening programme in Northern Portugal. J Med Screen 21:104-109, 2014
38. Özmen V, Özmen T, Doğru V: Breast Cancer in Turkey: An analysis of 20,000 patients with breast cancer. Eur J Breast Health 15:141-146, 2019
39. Weiss A, Chavez-MacGregor M, Lichtensztajn DY, et al: Validation study of the American Joint Committee on Cancer Eighth Edition prognostic stage compared with the anatomic stage in breast cancer. JAMA Oncol 4(2):203-209, 2018
39. O’Brien KM, Mooney T, Fitzpatrick P, et al: Screening status, tumour subtype, and breast cancer survival: A national population-based analysis. Breast Cancer Res Treat 172:133-142, 2018
40. Sala M, Domingo L, Louro J, et al: Survival and disease-free survival by breast density and phenotype in interval breast cancers. Cancer Epidemiol Biomarkers Prev 27:908-916, 2018
41. Özmen V, Güral SÖ, Cabioğlu N, et al: Cost-effectiveness of breast cancer screening in Turkey, a developing country: Results from Bahçeşehir Mammography Screening Project. Eur J Breast Health 13:117-122, 2017
42. Yuniar P, Robinson S, Moorin R, et al: Economic evaluation of breast cancer early detection strategies in Asia: A Systematic Review. Value Health Reg Issues 21:252-263, 2020
43. Ginsburg O, Yip CH, Brooks A, et al: Breast cancer early detection: A phased approach to implementation. Cancer 126:2379-2393, 2020 (suppl 10)
44. Kuhl CK: Abbreviated breast MRI for screening women with dense breast: The EA1141 trial. Br J Radiol 91:1090, 2018